Owlstone Medical, a biotech company based Cambridge, UK, has closed a Series E financing round at a sum of $27 million. This funding round was led by Ventura Capital and also involved Aviva Ventures and Horizons Ventures, as well as other existing investors.

The funds will be used to support the ongoing development of Owlstone’s proprietary Breath Biopsy platform, which has potential applications in early disease detection and precision medicine through the analysis of volatile organic compounds in breath samples, and the development and commercialisation of novel diagnostic tests and point of care devices.